- Home
- PYPL vs REGN Comparison
PYPL vs REGN Comparison
Compare PYPL & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPL
- REGN
- Stock Information
- Founded
- PYPL 1998
- REGN 1988
- Country
- PYPL United States
- REGN United States
- Employees
- PYPL N/A
- REGN N/A
- Industry
- PYPL Business Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- PYPL Consumer Discretionary
- REGN Health Care
- Exchange
- PYPL Nasdaq
- REGN Nasdaq
- Market Cap
- PYPL 64.3B
- REGN 59.5B
- IPO Year
- PYPL 2002
- REGN 1991
- Fundamental
- Price
- PYPL $67.11
- REGN $665.31
- Analyst Decision
- PYPL Hold
- REGN Buy
- Analyst Count
- PYPL 27
- REGN 21
- Target Price
- PYPL $81.39
- REGN $782.62
- AVG Volume (30 Days)
- PYPL 18.1M
- REGN 960.6K
- Earning Date
- PYPL 10-28-2025
- REGN 10-28-2025
- Dividend Yield
- PYPL 0.85%
- REGN 0.54%
- EPS Growth
- PYPL 18.59
- REGN 2.88
- EPS
- PYPL 4.98
- REGN 41.59
- Revenue
- PYPL $32,862,000,000.00
- REGN $14,247,800,000.00
- Revenue This Year
- PYPL $6.80
- REGN $1.34
- Revenue Next Year
- PYPL $6.00
- REGN $5.23
- P/E Ratio
- PYPL $13.31
- REGN $15.74
- Revenue Growth
- PYPL 4.47
- REGN 2.89
- 52 Week Low
- PYPL $55.85
- REGN $476.49
- 52 Week High
- PYPL $93.66
- REGN $834.42
- Technical
- Relative Strength Index (RSI)
- PYPL 46.74
- REGN 69.65
- Support Level
- PYPL $64.78
- REGN $640.99
- Resistance Level
- PYPL $67.43
- REGN $664.00
- Average True Range (ATR)
- PYPL 2.31
- REGN 18.85
- MACD
- PYPL -0.30
- REGN 3.69
- Stochastic Oscillator
- PYPL 17.84
- REGN 98.50
About PYPL PayPal Holdings Inc.
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 434 million active accounts at the end of 2024. The company also owns Venmo, a person-to-person payment platform.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).